Evoke Pharma Inc (EVOK)

NASDAQ
1.2700
+0.0400(+3.25%)
After Hours
1.2700
0.0000(0.00%)
- Real-time Data
  • Volume:
    130,586
  • Bid/Ask:
    1.2700/1.2900
  • Day's Range:
    1.1800 - 1.2700

EVOK Overview

Prev. Close
1.23
Day's Range
1.18-1.27
Revenue
350K
Open
1.24
52 wk Range
0.96-4.95
EPS
-0.32
Volume
130,586
Market Cap
41.2M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
504,883
P/E Ratio
-
Beta
1.16
1-Year Change
-73.15%
Shares Outstanding
32,439,380
Next Earnings Date
Nov 16, 2021
What is your sentiment on Evoke Pharma Inc?
or
Market is currently closed. Voting is open during market hours.

Evoke Pharma Inc News

Evoke Pharma Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuySell
Technical IndicatorsStrong BuyBuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell

Evoke Pharma Inc Company Profile

Evoke Pharma Inc Company Profile

Employees
5

Evoke Pharma, Inc. (Evoke) is a specialty pharmaceutical company. Evoke operates in the development and commercialization of pharmaceutical products. Evoke is focused primarily on the development and commercialization of drugs to treat gastrointestinal( GI) disorders and diseases. Evoke is developing its product Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide offering systemic delivery by nasal spray administration.

Read More
  • Turning from debt to profit...!!! Going to double soon!!!
    0
    • Should boom soon like a rocket...
      0
      • bankrupt soon
        1
        • the last call under usd3 !!!
          0
          • soon usd 4
            0
            • finally...quickly over usd 5
              0
              • 🐇
                0
                • 💸💵💰
                  0
                  • 💲
                    0
                    • 🐇
                      0
                      • Too Much technicals. Can you Correlate this into financials ?
                        0
                        • The bigger market for this drug is for off label use as an anti-emetic for postoperative patients having nausea and/or vomiting. The 2021 Medicare PQRS measures will include reducing outpatient admits for nausea and vomiting and the only currently available on intravenous or oral medications to treat patients at home after surgery are Compazine suppositories ( serious side reactions and people hate suppositories), or very expensive Zofran ODT ( oral dissolving tablets) that when you are already nauseated are not a great solution. The Intranasal route of Metoclopramide will be the most readily tolerated and should also be the most effective as loss of GI motility from general Anesthesia and from Narcotic pain medications is the primary cause of nausea and vomiting in the first few days post-op. This HUGE market will be driven by physicians looking for a means to ensure they capture the 10% Medicare hold back of PQRS.
                          0
                          • buyers will be pleased
                            0
                            • impatients are leaving.
                              0
                              • $7?
                                0
                                • Breaking $5 today ! Price target next 6 months ?
                                  0
                                  • Here we gooooo
                                    0
                                    • sellers will regret badly.
                                      0
                                      • What is your target for this?
                                        0
                                      • none.just right timing.
                                        0
                                    • get ready people.
                                      0
                                      • ready.
                                        0
                                        • Slowly but surely ticking up.... Mfg and sales plan news in the pipeline I guess
                                          0
                                          • Any news on this yet ? No momentum
                                            0
                                            • Target price next 6-12 months ? Anyone ?
                                              0
                                              • 10
                                                0
                                              • https://finance.yahoo.com/news/evoke-pharma-set-gain-170-025830940.html
                                                0
                                              • Hope so. I bought at 3:43....
                                                0
                                            • waiting for the spark to explode...first contract news
                                              0
                                              • you think so?
                                                0
                                              • that is what I expect. nothing is happening at the moment. more news should confirm that the target of $10 is realistic and then the upwards trend continues
                                                0
                                              • Any news for upward movement? Any thoughts ?
                                                0
                                            • big upward is coming...
                                              0
                                              • Any news on this for upward momentum?
                                                0
                                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.